Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript

Amgen reported strong Q2 2025 results, with revenues up 9% to $9.2 billion, driven by an impressive 13% volume growth and double-digit sales increases across 15 products, including key contributions from Repatha, UPLIZNA, and TEZSPIRE. The company highlighted significant pipeline advancements, particularly for its obesity drug MariTide, which is progressing well in multiple Phase III studies with a differentiated monthly dosing profile and strong efficacy, alongside positive data for oncology assets like IMDELLTRA, showing a 40% reduction in death risk in SCLC. Amgen increased its non-GAAP R&D spend by 18% to fuel late-stage programs and leverage AI, while reaffirming 2025 revenue guidance of $35.0-$36.0 billion and non-GAAP EPS of $20.20-$21.30, underscoring its commitment to innovation, volume-driven growth amidst industry pricing pressures, and disciplined capital allocation.

Analysis

Amgen reported a strong second quarter, with revenue growing 9% year-over-year to $9.2 billion, a result underpinned by a robust 13% increase in volume that successfully offsets industry-wide net selling price declines. This volume-driven performance was broad-based, with 15 individual products delivering double-digit sales growth. Key growth drivers included Repatha, with sales up 31% to $696 million, and the rare disease portfolio, which grew 19% to nearly $1.4 billion, now annualizing at over $5 billion. The oncology franchise also demonstrated strength, growing 14% to $2.2 billion, bolstered by the successful U.S. launch of IMDELLTRA, which generated $134 million in sales. While the portfolio showed widespread momentum, Prolia sales declined 4% to $1.1 billion due to biosimilar competition, a dynamic management indicated was unfolding as expected. Strategically, the company is aggressively funding its late-stage pipeline, evidenced by an 18% year-over-year increase in non-GAAP R&D spending. Significant focus is on the obesity drug MariTide, which is advancing through a comprehensive Phase III program with a differentiated monthly dosing profile, and IMDELLTRA, which showed a 40% reduction in the risk of death in small cell lung cancer. Upcoming catalysts, including the Repatha VESALIUS primary prevention data readout expected later this year, further highlight the pipeline's potential. The company reaffirmed its full-year 2025 revenue guidance of $35.0-$36.0 billion and non-GAAP EPS of $20.20-$21.30, signaling confidence in its dual strategy of commercial execution and innovation-led growth.

Key Decisions for Investors

• Investors should recognize the strength of Amgen's commercial execution, as the 13% volume growth demonstrates a resilient growth model capable of overcoming pricing pressures and biosimilar erosion on legacy products like Prolia.
• The late-stage pipeline represents a significant source of potential upside, and key catalysts to monitor include the Repatha VESALIUS cardiovascular outcomes data in H2 2025 and continued enrollment and data updates from the MariTide obesity program.
• Consider the company's financial discipline, which prioritizes heavy R&D investment (projected to grow over 20% in 2025) and debt reduction over significant share repurchases, a strategy focused on building long-term value through innovation.
• The successful launch of IMDELLTRA ($134 million in Q2) and the operational experience gained should be viewed as a positive read-through for the broader BiTE platform, including the potential future launch of xaluritamig in prostate cancer.